

**RECEIVED  
CENTRAL FAX CENTER**

**JUL 13 2006**

Attorney Docket No.: 6169.200-US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Liselotte Bjerre Knudsen

Serial No.: 09/800,541

Group Art Unit: 1647

Filed: March 7, 2001

Examiner: Romeo, David S.

Confirmation No. 4130

For: Lowering Serum Lipids

**FACSIMILE CERTIFICATE OF TRANSMISSION  
Via Facsimile No.: 571-273-8300**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO 1449
3. Copy of abstract (1 page)

is being deposited with the United States Patent and Trademark Office via facsimile no. 571-273-8300 on July 13, 2006.

Rashida Haji  
(name of person mailing paper)

Rashida Haji  
(signature of person mailing paper)

**RECEIVED  
CENTRAL FAX CENTER**

002/005

**JUL 13 2006**

Attorney Docket No.: 6169.200-US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Liselotte Bjerre Knudsen

Application No.: 09/800,541

Group Art Unit: 1647

Filed: March 7, 2001

Examiner: Romeo David S.

Confirmation No. 4130

For: Lowering Serum Lipids

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the reference is "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:

1. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study; Diabetes; 55(Suppl.1): A465


Attorney Docket No.: 6169.200-US  
Serial No.: 09/800,541

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached reference.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: July 13, 2006

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

**CUSTOMER NUMBER**

**23650**

PATENT TRADEMARK OFFICE

Sheet 1 of 1

|   |  |                                     |                       |
|---|--|-------------------------------------|-----------------------|
| FORM PTO-1449<br>(Rev. 2-02)  | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE | Atty. Docket No. 6169.200-US        | Serial No. 09/800,541 |
| INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT<br><br>(Use several sheets if necessary) |  | Applicant: Liselotte Bjerre Knudsen |                       |
|   |  | Filing Date March 7, 2001           | Group 1647            |

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |
|---------------------|--------------------|------|------|-------|----------|-------------------------------|
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |

## FOREIGN PATENT DOCUMENTS

|  | DOCUMENT<br>NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|--|--------------------|------|---------|-------|----------|-------------|----|
|  |                    |      |         |       |          | YES         | NO |
|  |                    |      |         |       |          |             |    |
|  |                    |      |         |       |          |             |    |
|  |                    |      |         |       |          |             |    |
|  |                    |      |         |       |          |             |    |
|  |                    |      |         |       |          |             |    |
|  |                    |      |         |       |          |             |    |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

|  |  |  |   |
|--|--|--|---|
|  |  |  | Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study; Diabetes; 55(Suppl.1): A465 |
|  |  |  |   |
|  |  |  |   |
|  |  |  |   |
|  |  |  |   |
|  |  |  |   |
|  |  |  |   |
|  |  |  |   |
|  |  |  |   |
|  |  |  |   |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.